Showing results (1-10 of 614) with videos related to

Sort By:
Pageof 62
Expert Opinion on Therapeutic Targets|September 12, 2007
Trial design for cancer (cell)-specific anticancer therapiesRobbert J van Alphen, J Verweij, F A L M Eskens
British Journal of Cancer|January 8, 2004
Angiogenesis inhibitors in clinical development; where are we now and where are we going?F A L M Eskens
British Journal of Cancer|March 22, 2007
Vascular disrupting agents in clinical developmentP Hinnen, F A L M Eskens
Drugs of Today (Barcelona, Spain : 1998)|February 17, 2018
Tivozanib: a new treatment option for renal cell carcinomaL Saes, F A L M Eskens
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumoursF A L M Eskens, H Dumez, R Hoekstra, et al.
British Journal of Cancer|September 30, 2010
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumoursC M L van Herpen, F A L M Eskens, M de Jonge, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 5, 2020
[As series of success stories; the pitfall of preoperative chemotherapy in unresectable carcinoma of the colon]E C T Geijteman, F A L M Eskens, H M Westgeest
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2014
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedulesP Hamberg, R H J Mathijssen, P de Bruijn, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933L van Zuylen, A Sparreboom, A van der Gaast, et al.
Pageof 62